Jhalak Dholakia, MD, Spotlights Ongoing Trial of Neoadjuvant Mirvetuximab Soravtansine in FRα-High Ovarian Cancer
An ongoing trial assessing neoadjuvant mirvetuximab soravtansine plus carboplatin in advanced folate receptor α–positive ovarian was reviewed by Jhalak Dholakia, MD, at The Society of Gynecologic Oncology 2022 Annual Meeting on Women’s Cancer.
Ira Winer, MD, PhD, Discusses Next Steps for Nemvaleukin Alfa Plus Pembrolizumab in Ovarian Cancer
Ira Winer, MD, PhD, FACOG, spoke about future directions of nemvaleukin alfa plus pembrolizumab for patients with pretreated platinum resistant ovarian cancer.
Clinical Case Presentation: A 53-Year-Old Woman with Metastatic ER/PR+ HER2+ Breast Cancer and Brain Metastases
Dr Stefania Maraka presents the case of a 53-year-old woman with de novo metastatic mutated ER/PR+ HER2+ breast cancer and brain metastases.
Treatment Options for HER2+ Breast Cancer After Progression on Tucatinib
Experts discuss their choice of systemic therapies after a patient with metastatic HER2+ breast cancer and brain metastases progresses on tucatinib therapy.
Nicolas Girard, MD, on Future Research Efforts With Nivolumab and Chemotherapy in Resectable NSCLC
In a conversation with CancerNetwork®, Nicolas Girard, MD, highlighted directions of future research with nivolumab and chemotherapy in patients with resectable non–small cell lung cancer.
Strategies and Barriers in mUC Maintenance Therapy
Panel members share insights into strategies and barriers to maintenance therapy for patients with bladder cancer.
Patient-Reported Outcome and Quality of Life Data on Maintenance Therapy
Thomas Powles, MBBS, MRCP, MD, comments on patient-reported outcome data and quality of life data in patients receiving maintenance therapy for metastatic urothelial cancer.
Conclusions: Lenvatinib + Pembrolizumab or Everolimus for Advanced Renal Cell Carcinoma
Brian Rini, MD, summarizes the thoughts of his colleagues on the use of lenvatinib plus pembrolizumab to treat advanced renal cell carcinoma.
The Exciting Future of Advanced Renal Cell Carcinoma Management
A panel of oncologists look at what’s in the pipeline for advanced renal cell carcinoma, including trials and treatment options.
Unmet Needs in Advanced Renal Cell Carcinoma Management
Two kidney cancer experts explore the current unmet needs for patients with advanced renal cell carcinoma.
Safety and Efficacy Data: The CheckMate 9ER Trial
Robert Alter, MD, reviews the CheckMate 9ER trial of cabozantinib/nivolumab versus sunitinib in advanced renal cell cancer.
Safety and Efficacy Data: The KEYNOTE-426 Trial
Arnab Basu, MD, MPH, FACP discusses data from the KEYNOTE-426 trial of axitinib/pembrolizumab versus sunitinib in metastatic RCC.
Renal Cell Carcinoma: Future Directions in Care
Closing out their discussion on renal cell carcinoma management, experts highlight unmet needs and look toward the future treatment landscape.
Treatment Strategies for Patients Who Progress on Adjuvant Pembrolizumab
Following the advent of adjuvant pembrolizumab in high-risk renal cell carcinoma, experts consider treatment strategies for patients who progress on adjuvant pembrolizumab.
Daniel P. Petrylak, MD, Talks About Importance of Mentorships in Genitourinary Oncology
At the 15th Annual Interdisciplinary Prostate Cancer Congress® and Other Genitourinary Malignancies, Daniel P. Petrylak, MD, reflects upon mentorship during his training to become an oncologist.
Catherin Watson, MD, Discusses Designing a Trial on Genetic Testing Education in Ovarian Cancer
At SGO 2022, Catherine Watson, MD, spoke about the 2 arms of a randomized education trial presented at the conference.
Nicolas Girard, MD, on the Rationale and Design of the Phase 3 CheckMate 816 Trial in Resectable NSCLC
In an interview with CancerNetwork®, Nicolas Girard, MD, discussed the rationale for assessing nivolumab and chemotherapy in resectable non–small cell lung cancer and the design of the phase 3 CheckMate 816 trial.
Matthew Krebs, MB, PhD Discusses Phase 1 PALOMA Trial Results of Subcutaneous Amivantamab in Solid Tumors
Matthew Krebs, MB, PhD spoke about efficacy of subcutaneous amivantamab observed in the phase 1 PALOMA trial for patients with solid tumors.
Factors in Selecting Therapy for Non-Small Cell Lung Cancer
Expert panelists look at all factors that inform treatment selection when managing a patient diagnosed with non–small cell lung cancer.
Biomarker Testing Practices in Non-Small Cell Lung Cancer
Comprehensive discussion on how biomarker testing and multidisciplinary care can improve the management of non–small cell lung cancer.
.png%3Ffit%3Dcrop%26auto%3Dformat&w=3840&q=75 "In a conversation with CancerNetwork®, Nicolas Girard, MD, highlighted directions of future research with nivolumab and chemotherapy in patients with resectable non–small cell lung cancer.")
.png%3Ffit%3Dcrop%26auto%3Dformat&w=3840&q=75 "Strategies and Barriers in mUC Maintenance Therapy")
